The IFN signature has been observed in the blood and tissue cells of patients with systemic lupus erythematosus (SLE) and other autoimmune diseases, where it serves as a biomarker of active disease and influences treatment selection [14]. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.